Surrozen, Inc./DE
Surrozen develops Wnt-based biologics for sight-threatening ophthalmic conditions.
SCHEDULE 13G/AAug 14Latest SEC filing
Aug 6Latest story
August 2026
Sign inSign inSurrozen develops Wnt-based biologics for sight-threatening ophthalmic conditions.